{"DataElement":{"publicId":"2656661","version":"1","preferredName":"AIDS Malignancy Consortium Patient Exclusion Clinical Trial Eligibility Criteria 048 Type","preferredDefinition":"the type of element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_E_CTEC_048_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2518234","version":"1","preferredName":"AIDS Malignancy Consortium Patient Exclusion Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by the NCI.","longName":"AMC_PT_EXCLU_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2518228","version":"1","preferredName":"AIDS Malignancy Consortium Patient","preferredDefinition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.:A person who requires medical care.","longName":"C19707:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS Malignancy Consortium","conceptCode":"C19707","definition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08C6-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518232","version":"1","preferredName":"Exclusion Clinical Trial Eligibility Criteria","preferredDefinition":"Exclusion; the act of restricting entrance or barring from participation.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25370:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exclusion Criteria","conceptCode":"C25370","definition":"Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC88111-1844-69E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC88111-1855-69E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2656640","version":"1","preferredName":"048 Exclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility exclusion criteria for an AIDS Malignancy Consortium 048 protocol. ","longName":"048_EXCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"If the participant is female, is she pregnant or breast-feeding","valueDescription":"If the participant is female, is she pregnant or breast-feeding","ValueMeaning":{"publicId":"2649481","version":"1","preferredName":"If the participant is female, is she pregnant or breast-feeding","longName":"2649481","preferredDefinition":"If the participant is female, is she pregnant or breast-feeding","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32655A77-934F-3C34-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"33421D68-489C-0D9F-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"ONEDATA","dateModified":"2007-06-19","deletedIndicator":"No"},{"value":"Has the participant received previous therapy for BL or atypical BL other than seven consecutive days of steroids","valueDescription":"Has the participant received previous therapy for BL or atypical BL other than seven consecutive days of steroids","ValueMeaning":{"publicId":"2656659","version":"1","preferredName":"Has the participant received previous therapy for BL or atypical BL other than seven consecutive days of steroids","longName":"2656659","preferredDefinition":"Has the participant received previous therapy for BL or atypical BL other than seven consecutive days of steroids","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3341EE51-29A8-18DA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3341EEFB-C4A8-18D6-E044-0003BA3F9857","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"ONEDATA","dateModified":"2007-06-19","deletedIndicator":"No"},{"value":"Does the participant have any medical illness unrelated to NHL, which in the opinion of the attending physician and Principal Investigator (PI), will preclude administration of chemotherapy safely","valueDescription":"Does the participant have any medical illness unrelated to NHL, which in the opinion of the attending physician and Principal Investigator (PI), will preclude administration of chemotherapy safely","ValueMeaning":{"publicId":"2656658","version":"1","preferredName":"Does the participant have any medical illness unrelated to NHL, which in the opinion of the attending physician and Principal Investigator (PI), will preclude administration of chemotherapy safely","longName":"2656658","preferredDefinition":"Does the participant have any medical illness unrelated to NHL, which in the opinion of the attending physician and Principal Investigator (PI), will preclude administration of chemotherapy safely","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3341C1D9-A08C-1B53-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3341EEFB-C4BA-18D6-E044-0003BA3F9857","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"ONEDATA","dateModified":"2007-06-19","deletedIndicator":"No"},{"value":"Does the participant have a history of any malignancy for which the disease-free interval is <5 years, excluding curatively treated cutaneous basal cell or squamous cell carcinoma and carcinoma in situ of the cervix or cutaneous KS","valueDescription":"Does the participant have a history of any malignancy for which the disease-free interval is <5 years, excluding curatively treated cutaneous basal cell or squamous cell carcinoma and carcinoma in situ of the cervix or cutaneous KS","ValueMeaning":{"publicId":"2656657","version":"1","preferredName":"Does the participant have a history of any malignancy for which the disease-free interval is <5 years, excluding curatively treated cutaneous basal cell or squamous cell carcinoma and carcinoma in situ of the cervix or cutaneous KS","longName":"2656657","preferredDefinition":"Does the participant have a history of any malignancy for which the disease-free interval is <5 years, excluding curatively treated cutaneous basal cell or squamous cell carcinoma and carcinoma in situ of the cervix or cutaneous KS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3341C0EF-7D9E-18E2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3341EEFB-C4CC-18D6-E044-0003BA3F9857","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"ONEDATA","dateModified":"2007-06-19","deletedIndicator":"No"},{"value":"Is the participant already receiving erythropoietin or G-CSF for treatment of HIV-related cytopenia","valueDescription":"Is the participant already receiving erythropoietin or G-CSF for treatment of HIV-related cytopenia","ValueMeaning":{"publicId":"2656656","version":"1","preferredName":"Is the participant already receiving erythropoietin or G-CSF for treatment of HIV-related cytopenia","longName":"2656656","preferredDefinition":"Is the participant already receiving erythropoietin or G-CSF for treatment of HIV-related cytopenia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3341C4D3-694E-18D4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3341EEFB-C4DE-18D6-E044-0003BA3F9857","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"ONEDATA","dateModified":"2007-06-19","deletedIndicator":"No"},{"value":"If yes, will the growth factors be discontinued at least 24 hours prior to chemotherapy","valueDescription":"If yes, will the growth factors be discontinued at least 24 hours prior to chemotherapy","ValueMeaning":{"publicId":"2656655","version":"1","preferredName":"If yes, will the growth factors be discontinued at least 24 hours prior to chemotherapy","longName":"2656655","preferredDefinition":"If yes, will the growth factors be discontinued at least 24 hours prior to chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3341E820-21B5-1A75-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3341EEFB-C4F0-18D6-E044-0003BA3F9857","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"ONEDATA","dateModified":"2007-06-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"33421D68-4837-0D9F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Exclusion Criteria","type":"Preferred Question Text","description":"Exclusion Criteria","url":null,"context":"CTEP"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"33418232-A907-1A8F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-19","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}